Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

Details Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

2007-02-13

2007-02-13

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C540S455000, C540S460000

Reexamination Certificate

active

10826743

ABSTRACT:
The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

REFERENCES:
patent: 6329379 (2001-12-01), Llinas-Brunet et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 2002/0037998 (2002-03-01), Llinas-Brunet et al.
patent: WO-00/09543 (2000-02-01), None
patent: WO-00/59929 (2000-10-01), None
patent: WO-2003/053349 (2003-07-01), None
patent: WO-2004/072243 (2004-08-01), None
M. Llin{dot over (a)}s-Burnet, et al., “Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease,” Bioorganic & Medicinal Chemistry Letters 8, (1998), pp. 1713-1718.
A. Spatola, “Peptide Backbone Modifications: A Structure-Activity Analysis of Peptides Containing Amide Bond Surrogates, Conformational Constraints, and Rela, ” Department of Chemistry, University of Louisville, Louisville Kentucky, pp. 267-357, XP 002032461.

Affiliated with

Also associated with

Rating

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3826247